RESUMEN
Objective:To explore the clinical effect of compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel in the treatment of facial hormone-dependent dermatitis. Methods:Totally 108 patients with facial hormone-dependent dermatitis were selected randomly and divided into the control group(n = 54) and the treatment group(n =54). The control group was treated with desloratadine and 0.1% tacrolimus ointment;and the treatment group was treated with compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel additionally on the basis of control group. The clinical efficacy of the two groups was evaluated,and the improvement of symptoms and objective signs before and after the treatment was compared. The adverse reactions were recorded as well. Results:The total effective rate of the treatment group after one-month and two-month treatment was 75.93% and 90.74%, respectively, which were both higher than those of the control group(P < 0.05). The scores of symptoms and objective signs and the total scores of disease of the treatment group after one-month and two-month treatment and two-month follow-up were all lower than those of the control group, and the differences were statistically significant(P <0.05). The disappearance time of objective signs and the incidence of facial adverse reactions were both lower than those of the control group,and the differences were statistically significant(P < 0.05),however, the incidence of dry mouth in the treatment group was higher than that in the control group(P < 0.05). Conclusion:Compound glycyrrhizin tablets combined with recombinant bovine basic fibroblast growth factor gel has better clinical effect for the therapy of facial hormone-dependent dermatitis,which can improve the symptoms significantly with high application security.
RESUMEN
Objective To study the clinical effects of recombinant human epidermal growth factor (rhEGF) gel combined with tacrolimus treatment on facial hormone-dependent dermatitis, and to investigate its influence in skin function and recurrence of dermatitis. Methods Forty-eight outpatients with facial hormone-dependent dermatitis were randomly divided into treatment group (n=24, treatment with tacrolimus combined rhEGF gel) and control group (n=24, treatment with tacrolimus). The moisture of skin, sebum content and transepidermal water loss (TEWL) were examined before treatment and 4 weeks after treatment in two groups. Eczema area and severity index (EASI) were calculated at 1 week, 2 weeks and 4 weeks after treatment. The adverse reactions and recurrence of dermatitis were observed during the treatment as well. Results Compared with pre-treatment, the moisture of skin and sebum content were increased (P0.05), but it is much higher in treatment group after two-week treatment (79.2%vs. 50.0%, P<0.05) and after four-week treatment (91.2% vs. 62.5%, P<0.05). Furthermore, there was no adverse reaction in the treatment group, and the recurrence rate was much lower in treatment group (12.5%) than that of the control group (37.5%,χ2=4.03,P<0.05). Conclusion Recombinant human epidermal growth factor gel has an auxiliary curative effect on facial hormone-dependent dermatitis and can significantly improve skin function, and the recurrence rate of dermatitis is low.
RESUMEN
This study was aimed to observe the mechanism of Jia-Jian Xiao-Yao (JJXY) Powder improving facial skin barrier function of the hormone-dependent dermatitis patients. A total of 100 patients were randomly divided into two groups. In the treatment group, 50 cases were orally administered with JJXY Powder. In the control group, loratadine and vitamin EC particles were orally administered to the 50 cases. Thirty days is one treatment course. Changes of transepidermal water loss (TEWL), skin erythema amount and IL-4 were detected in patients of both groups before and after the treatment. The results showed that the clinical efficiency of treatment group and control group was 82.0% and 58.0%, respectively. In the treatment group, the TEWL and skin erythema amount were obviously decreased after the treatment (P < 0.05). In the treatment group, the decreasing range of serum IL-4 was significant compared to control group (P < 0.05). It was concluded that JJXY Powder is one of the effective methods for the treatment of facial hormone-dependent dermatitis. It is able to repair facial hormone-dependent dermatitis in patients with impaired skin barrier function and reduce the amount of skin erythema. The therapeutic mechanism may be related to the regulation of serum IL-4.